Overview
Joseph C. Murray, M.D., Ph.D. is an Assistant Professor of Oncology at the Sidney Kimmel Comprehensive Cancer at Johns Hopkins in the Upper Aerodigestive Cancer Division (UAD). He is Co-Director of the Lung Cancer Precision Medicine Center of Excellence (PMCOE) and directs the UAD Immunotherapy Database. Dr. Murray received his undergraduate degree in Molecular Cell Biology from the University of California, Berkeley in 2003. After working in the biotechnology industry, he went on to receive his medical and graduate degree in Interdisciplinary Tumor Biology at Georgetown University School of Medicine in 2015. After completing internship and residency in the Osler Medical Residency Training Program at Johns Hopkins Hospital, he remained at Johns Hopkins to complete his fellowship in Medical Oncology in the Sidney Kimmel Comprehensive Cancer Center. Dr. Murray conducts translational research in cancer genomics, liquid biopsy, and immunology in non-small cell lung cancer. He also has expertise in antibody-based immunotherapy, molecular and cell biology, and bioinformatics. He integrates research through the Lung Cancer PMCOE and UAD Immunotherapy Database to conduct observational clinical studies in real-world populations of patients with thoracic cancer. He cares for patients primarily at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center at Bayview Medical Center.
Dr. Murray is rated as an Advanced provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Pleuropulmonary Blastoma, Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, and Small Cell Lung Cancer (SCLC).
His clinical research consists of co-authoring 45 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Small Cell Lung Cancer (SCLC).
Insurance
Accepted insurance can change. Please verify directly with the provider.
Accepted insurance plans:
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- POS
- PPO
- HMO
- POS
- PPO
- EPO
- HMO
- PPO
- INSURANCE PLAN
- MEDICARE PDP
- PPO
- HMO
- POS
- PPO
- HMO
- INDEMNITY
- POS
- PPO
- HMO
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE-MEDICAID PLAN
- OTHER MANAGED MEDICAID
- OTHER MEDICAID
- STATE MEDICAID
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE PART D
- EPO
- HMO
- POS
- PPO
- EPO
- HMO
- INSURANCE PLAN
- MANAGED MEDICAID PLAN
- MEDICARE MAPD
- MEDICARE PDP
- MEDICARE SNP
- MEDICARE-MEDICAID PLAN
- OTHER MEDICARE
- OTHER MEDICARE PART D
Locations
300 Mason Lord Drive, Kimmel Cancer Center, Kimmel Cancer Center, Baltimore, MD 21224
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Johns Hopkins Bayview Medical Center
Christine L Hann, completed her MD and Ph.D. at Jefferson Medical College/Thomas Jefferson University follwed by an internal medicine residency at the University of Chicago Hospitals. Following a fellowship at Johns Hopkins University in Hematology and Oncology, Dr. Hann joined the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center as a member of the Upper Aerodigestive Cancer Program and sees patients with non-small cell and small cell lung cancer. Dr. Hann's research focus is on developing novel therapeutics for lung cancer, particularly small cell lung cancer (SCLC) and neuroendocrine tumors (NETs) such as carcinoid tumors of the lung. As a faculty member she is involved in both clinical and laboratory research. Specific research projects include: 1) Studying mechanisms of resistant to small molecule inhibitors of the antiapoptotic protein, BCL-2 using patient-derived xenograft models. Her preclinical work has led to an NCI-sponsored Phase 1/2 clinical trial combining a BCL-2 inhibitor with a TORC1/2 inhibitors which is currently underway (NCT03366103). 2) Preclinical evaluation of various therapeutics including epigenetic modulators (LSD1 inhibitors) and nanoliposome chemotherapy in SCLC PDXs; 3) Modeling and characterizing chemoradiotherapy resistance in preclinical models of SCLC. She, along with Dr. Luigi Marchionni in Biostatistics and Dr. Phuoc Tran in the Department of Radiation Oncology, were recently awarded a 5-year NCI-sponsored U01 grant to study mechanisms of chemoradiation resistance in SCLC. Dr. Hann is PI of several trials in SCLC and NSCLC and is leading investigator-initiated clinical trials in SCLC and NETs. Dr. Hann is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). Her top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), and Squamous Cell Lung Carcinoma.
University Of Maryland Oncology Associates PA
Taofeek Owonikoko is a Hematologist Oncology specialist and a Hematologist in Baltimore, Maryland. Dr. Owonikoko is rated as an Elite provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Owonikoko is currently accepting new patients.
Medstar Medical Group Ii LLC
Stephen Liu is an Oncologist and a Hematologist in Washington, Washington, D.c.. Dr. Liu is rated as a Distinguished provider by MediFind in the treatment of Small Cell Lung Cancer (SCLC). His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Tissue Biopsy. Dr. Liu is currently accepting new patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Advanced
- EGFR Positive Lung CancerDr. Murray isAdvanced. Learn about EGFR Positive Lung Cancer.
- Lung CancerDr. Murray isAdvanced. Learn about Lung Cancer.
- Non-Small Cell Lung Cancer (NSCLC)
- Pleuropulmonary BlastomaDr. Murray isAdvanced. Learn about Pleuropulmonary Blastoma.
- Small Cell Lung Cancer (SCLC)Dr. Murray isAdvanced. Learn about Small Cell Lung Cancer (SCLC).
- Experienced
- ALK-Positive Non-Small Cell Lung CancerDr. Murray isExperienced. Learn about ALK-Positive Non-Small Cell Lung Cancer.
- Brain TumorDr. Murray isExperienced. Learn about Brain Tumor.
- Gastroesophageal Junction CancerDr. Murray isExperienced. Learn about Gastroesophageal Junction Cancer.
- Large-Cell Lung CarcinomaDr. Murray isExperienced. Learn about Large-Cell Lung Carcinoma.
- Lung AdenocarcinomaDr. Murray isExperienced. Learn about Lung Adenocarcinoma.
- MelanomaDr. Murray isExperienced. Learn about Melanoma.